Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(9):643-644; doi:10.1093/jnci/djj168
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fisher, B.
Right arrow Articles by Costantino, J. P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fisher, B.
Right arrow Articles by Costantino, J. P.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

CORRESPONDENCE

RESPONSE: Re: Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Bernard Fisher, Joseph P. Costantino

Affiliations of authors: Department of Surgery (BF), Department of Biostatistics (JPC), University of Pittsburgh, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA (BF, JPC)

Correspondence to: Bernard Fisher, MD, 300 Halket St., Suite 350, Pittsburgh, PA 15213 (e-mail: fisherb2@upmc.edu).

The first 10% of the full text of this article appears below.

Cuzick et al. contend that it was inappropriate both to announce the results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) prevention trial (P-1) (1,2) and to unblind the participants. They argue that those actions make it difficult to interpret the data from P-1 and that important information has been lost. We disagree.

We question some key points in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Jack Cuzick, John F. Forbes, and Anthony Howell
J Natl Cancer Inst 2006 98: 643. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
Y. Shen, J. P. Costantino, and J. Qin
Tamoxifen Chemoprevention Treatment and Time to First Diagnosis of Estrogen Receptor-Negative Breast Cancer
J Natl Cancer Inst, October 15, 2008; 100(20): 1448 - 1453.
[Abstract] [Full Text] [PDF]